← Back to headlines
Johnson & Johnson Partners with Sail Biomedicines to Advance CAR-T Cancer Therapy Pipeline
J&J has entered a strategic collaboration with biotech firm Sail Biomedicines to accelerate its chimeric antigen receptor T-cell development, aiming to outpace rival Bristol Myers Squibb in the immunotherapy space.
29 Aug, 02:28 — 29 Aug, 02:28
Sources
Showing 1 of 1 sources
Related Stories
US-Iran Military Escalation Sparks Retaliatory Strikes and Market Volatility
29m ago
BP Appoints Ian Tyler as New Chairman Following Leadership Transition
35m ago
Everus Construction and California Resources Finalize Major Corporate Acquisitions
54m ago
Nvidia Nears $14 Billion Acquisition of AI Startup Hugging Face
1h ago